USPTO serial 98788240
NIAGEN
Reviewed by CopyMark Law Group
Status 645Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- NISHIGAYA, CHRISTINE EIKO
- Law office
- TMO LAW OFFICE 132
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with NIAGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Los Angeles, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Susan M. Natland
Susan M. Natland Baker & Hostetler LLP600 Anton Boulevard, Suite 900Costa Mesa, CA 92626-7221United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Active chemical ingredients for use in the manufacturing of dietary supplements, nutritional supplements, pharmaceuticals, cosmetics, cosmetic preparations, pet products being nutritional supplements for animals, and personal care products; chemical reagents for non-medical purposes; chemicals for use in industry and science; chemicals for use in the biochemical and chemical industry; assays for research purposes; diagnostic preparations for scientific or research use; test kits comprised of chemical preparations and chemical reagents for testing biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for scientific research purposes, other than for medical or veterinary use; test kits comprised of chemical agents and chemical preparations for testing biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for scientific research purposes, other than for medical or veterinary use; specimen collection kits comprised primarily of chemically treated non-medical test strips and chemically treated non-medical test media in the form of cards and also including, laboratory swabs, plastic bags for transmitting specimens, printed mailing labels, and tubes for holding specimens for scientific research purposes, other than for medical or veterinary use; test kits comprised of chemical agents and chemically treated non-medical test media in the form of a card for testing for markers in bodily fluids, liquids, saliva and tissue for non-medical purposes; chemical preparations and articles, namely, chemical test paper, chemically treated non-medical test media in the form of strips and cards for the testing of nicotinamide adenine dinucleotide levels for purposes of assessing cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging for scientific purposes, other than for medical or veterinary use | ACTIVE | — |
| 005 | Pharmaceutical preparations, namely, nicotinamide riboside chloride for injection; injectable pharmaceutical preparations for use in hydration, vitamin, healthy aging, and wellness therapies; injectable pharmaceutical preparations for increasing health, healthy aging, cellular health, cellular repair, energy, heart health, and muscle health; pharmaceutical preparations, namely, nicotinamide riboside chloride for use in intravenous therapy; medical diagnostic assays for testing of bodily fluids for analyzing biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for medical purposes; diagnostic kits comprised of medical diagnostic test media in the form of a card and sanitizing wipes for testing biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for medical purposes; diagnostic kits comprising diagnostic agents and preparations for medical purposes; specimen collection kits for medical purposes comprised primarily of swabs for medical purposes and also including medical diagnostic test strips for blood analysis, plastic bags for transmitting medical specimens, printed mailing labels, and tubes for holding specimens; medical test kits comprised primarily of swabs for medical purposes, medical diagnostic media in the form of test strips and cards for testing blood for analysis of biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for medical purposes, and also including lancets, adhesive bandages, plastic bags for transmitting medical specimens, and printed mailing labels for testing for markers in bodily fluids, saliva and tissue; diagnostic agents, preparations and substances for medical purposes; medical and veterinary diagnostic preparations and articles, namely, swabs for medical use, medical diagnostic test media in the form of strips and cards for blood analysis in the testing nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging; nutritional supplements for increasing health, healthy aging, cellular health, cellular repair, energy, heart health, muscle health, and for treating vitamin, metabolite, enzyme, and nicotinamide adenine dinucleotide deficiencies, all for promoting nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging for medical and veterinary use; pharmaceutical preparations for increasing health, healthy aging, cellular health, cellular repair, energy, heart health, muscle health, and for treating vitamin, metabolite, enzyme, and nicotinamide adenine dinucleotide deficiencies, all for promoting nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging for medical and veterinary use; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations, all for promoting nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging for medical and veterinary use; prefilled syringes being syringes sold filled with pharmaceutical preparations, namely, vitamins, and nicotinamide adenine dinucleotide precursors; injectors sold filled with pharmaceutical preparations, namely, vitamins and nicotinamide adenine dinucleotide precursors; prefilled syringes sold filled with pharmaceutical preparations, namely, nicotinamide adenine dinucleotide precursors for promoting nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging; injectors sold filled with pharmaceutical preparations, namely, nicotinamide adenine dinucleotide precursors for promoting nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging; prefilled syringes sold filled with nicotinamide riboside chloride; injectors sold filled with nicotinamide riboside chloride; pharmaceutical preparations, namely, nicotinamide riboside chloride in the form of an injectable pharmaceutical | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 9, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Oct 9, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jul 13, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 13, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 13, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 9, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 8, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 8, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 6, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Mar 6, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Feb 5, 2026 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Feb 5, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 5, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 5, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 5, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 5, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 8, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 8, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 8, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 28, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 28, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 28, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 11, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 11, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 11, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 16, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 16, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 16, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 16, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 16, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 16, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 10, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 9, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 7, 2024 | NWAP | NEW APPLICATION ENTERED | — |